Product Name

Ergotamine Tartrate

Name: Ergotamine Tartrate - LGM Pharma
SKU: 379-79-3

CAS Number

379-79-3

LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Ergotamine Tartrate

CAS Number:

379-79-3

Indication:

Ergotamine tartrate and caffeine tablets are indicated as a combination therapy to both stop and prevent vascular headaches, migraine headaches and cluster migraines.

Mode of Action:

As part of the ergot alkaloid family, Ergotamine iwas one of the first ergot alkaloids to be isolated. The plentiful vasoconstrictor activities of Ergotamine Tartrate includes positive inhibitory effects on neurogenic inflammation.

Pharmacodynamics:

Ergotamine is an alpha adrenergic blocking agent that offers a direct stimulating effect on the blood vessels, thus producing a depression of the central vasomotor centers.

Metabolism:

Ergotamine is metabolized in the liver with over 90 percent of the metabolites excreted in the bile as a 2 hour half-life.

Toxicity:

Over dosage of Ergotamine Tartrate can be a concern and this has been documented. Symptoms of Ergotism, or an overdose of Ergotamine include vomiting, cyanosis, coma, convulsions and shock. While rare, caution should be taken by patients not to overdose on Ergotamine or products containing this drug. Side effects, albeit mild, reported from patients who took Ergotamine include nausea and dizziness.

PubChem:

8223

Formula:

C33H35N5O5)2, C4H6O6

Molecular Mass:

1312.4

Synonyms:

(5'alpha)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione

SMILES:

[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O

InChi:

S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1

General Reference:

Headache. 2010.
Young, WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives. Headache. 37 Suppl 1:S42-5, 1997.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

Ergotamine Tartrate

379-79-3

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product